European regulator accepts to review Mylan’s MAA for insulin glargine
The insulin glargine, which has been co-developed by Mylan and Biocon, is used to treat adults with Type 2 diabetes and adults and paediatric patients with type 1 diabetes.
top of page
bottom of page